Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer
Clinical trial NCT07107217 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07107217
- Sponsor
- Blokhin's Russian Cancer Research Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-01
- Primary completion
- 2026-12-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.